Symbols

SRPT

Sarepta·NASDAQ

--(--)

SRPT fundamentals

SRPT Q4 2025 Earnings

Sarepta (SRPT) released its earnings on Feb 25, 2026: revenue was 442.93M (YoY -32.73%), beat estimates; EPS was -3.93 (YoY -362.00%), missed estimates.

Revenue / YoY

442.93M

-32.73%

EPS / YoY

-3.93

-362.00%

Report date

Feb 25, 2026

SRPT Earnings Call Summary for Q4,2025

Financial Resilience: $954M cash, 2026 net product revenue guidance $1.2B-$1.4B, and positive cash flow driven by PMOs and ELEVIDYS.
ELEVIDYS Reset: 2026 revenue potential $500M+ if educational campaigns succeed; 70%+ ambulatory patients untreated.
Pipeline Breakthroughs: siRNA programs for DM1, FSHD, and Huntington's advancing; Phase I/II data expected Q2 2026.
Leadership Transition: Doug Ingram retiring by end-2026; Board prioritizing patient-focused successor.
Japan Expansion: $40M milestone payment Q1 2026 from Roche on first ELEVIDYS sale in Japan.

Earnings

EPS

Revenue

Revenue & Expenses

SRPT has released its 2025 Q4 earnings report, with revenue of 442.93M, reflecting a YoY change of -32.73%, and net profit of -412.23M, showing a YoY change of -359.18%. The Sankey diagram below clearly presents SRPT's revenue sources and cost distribution.

Key Indicators

Sarepta (SRPT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Sarepta (SRPT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Sarepta (SRPT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Sarepta (SRPT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown